Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PPLPHARMA.NS
HoldHot AirPiramal Pharma Limited · Healthcare · India · $3.2B · Avg Vol: $14M/d
58
StockRankGet insider-trade alerts
Q
42
V
31
M
80
P/E (TTM)
—
ROE
-4.0%
D/E
0.7x
Dividend %
—
COMPANY DESCRIPTION
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.3B | 81.1B | 90.6B | 87.6B | 7.6% | 92.4B | 101.1B | 115.7B | 15.0% |
| EPS (INR) | -1.54 | 0.14 | 0.69 | -2.46 | 392.9% | -2.37 | — | — | — |
| Shares | 1.2B | 1.3B | 1.3B | 1.3B | +8.8% | 1.3B | — | — | — |
| Debt | 56.4B | 47.1B | 48.6B | 56.7B | 0.2% | 57.3B | — | — | — |
| Equity | 67.7B | 79.1B | 81.3B | 81.6B | 6.4% | — | — | — | — |
| Op CF | 4.8B | 10.0B | 8.9B | 16.5B | 50.6% | 16.6B | — | — | — |
| Inv CF | -13.4B | -4.3B | -4.8B | -8.3B | — | — | — | — | — |
| Fin CF | 8.2B | -4.2B | -4.4B | -389.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+11.4%
SMA 50SMA 200
Close
$2.28
RSI (14)
57.6
52W High
$2.43
From 52W High
0.9%
SCORE BREAKDOWN
Quality
42
ROIC
1.2%46.6
ROE
-4.0%40.2
GP/Assets
30.4%64.4
Op. Margin
-1.2%32.1
FCF/Assets
4.2%66.8
Piotroski
25.9
Int. Cover
0.5x37.4
D/E Ratio
0.70x20.6
Current Ratio
1.51x26.5
Value
31
P/E (TTM)
—N/A
EV/EBITDA
38.3x16.1
P/FCF
39.5x38.6
P/B
3.5x39.7
P/S
3.1x55.3
Div Yield
—N/A
Momentum
80
52W High %
94%91.9
RS 6M
44%89.7
SMA 50/200
1.14x82.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+273%91.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$3.2B
P/E (Forward)
53.5x
Gross Margin
59.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PPLPHARMA.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PPLPHARMA.NS | Piramal Pharma Limited(you) | $3.2B | 58 | Hold |
| NEULANDLAB.NS | Neuland Laboratories Limited | $3.2B | 64 | Hold |
| WOCKPHARMA.NS | Wockhardt Limited | $3.8B | 54 | Hold |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 56 | Hold |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| EMCURE.NS | Emcure Pharmaceuticals Limited | $3.9B | 81 | Strong Buy |
| NATCOPHARM.NS | NATCO Pharma Limited | $1.6B | 72 | Buy |
| AJANTPHARM.NS | Ajanta Pharma Limited | $4.7B | 79 | Buy |
Peer medians: ROE 11.9% · P/E 42.5x · Gross margin 59.4%